These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29625424)

  • 1. mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.
    Sebastianutto I; Cenci MA
    Curr Opin Pharmacol; 2018 Feb; 38():81-89. PubMed ID: 29625424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into pathogenesis of l-DOPA-induced dyskinesia.
    Zheng C; Zhang F
    Neurotoxicology; 2021 Sep; 86():104-113. PubMed ID: 34331976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide, a new player in L-DOPA-induced dyskinesia?
    Del-Bel E; Padovan-Neto FE; Bortolanza M; Tumas V; Aguiar AS; Raisman-Vozari R; Prediger RD
    Front Biosci (Elite Ed); 2015 Jan; 7(1):168-92. PubMed ID: 25553372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
    Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
    Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
    Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
    Amalric M
    Curr Opin Pharmacol; 2015 Feb; 20():29-34. PubMed ID: 25462289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiological clues to therapeutic applications of glutamate mGlu5 receptor antagonists in levodopa-induced dyskinesia.
    Pourmirbabaei S; Dolatshahi M; Rahmani F
    Eur J Pharmacol; 2019 Jul; 855():149-159. PubMed ID: 31063776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
    Iderberg H; Rylander D; Bimpisidis Z; Cenci MA
    Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
    Lopez S; Bonito-Oliva A; Pallottino S; Acher F; Fisone G
    J Parkinsons Dis; 2011; 1(4):339-46. PubMed ID: 23939343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism of metabotropic glutamate receptor type 5 prevents levodopa-induced dyskinesia development in a male rat model of Parkinson's disease: Electrophysiological evidence.
    Kamo H; Iwamuro H; Nakamura R; Nojiri S; Okuzumi A; Ogawa T; Nakajima A; Hattori N; Shimo Y
    J Neurosci Res; 2024 Mar; 102(3):e25302. PubMed ID: 38515319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: bridging molecular studies and clinical trials.
    Vallano A; Fernandez-Duenas V; Garcia-Negredo G; Quijada MA; Simon CP; Cuffí ML; Carbonell L; Sanchez S; Arnau JM; Ciruela F
    CNS Neurol Disord Drug Targets; 2013 Dec; 12(8):1128-42. PubMed ID: 24040811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
    Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Pharmacol Rev; 2013 Jan; 65(1):171-222. PubMed ID: 23319549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.